UroGen makes a gel that turns liquid at body temperature, letting doctors deliver chemo directly into the bladder or kidney to treat non-invasive cancers without surgery. Think of it as a slow-release drug depot that stays put instead of washing away with urin
Money comes from selling Jelmyto and Zusduri, both mitomycin-based gels for bladder cancer. Gross margins are high at ~90%, but the company is still unprofitable—net losses were USD 0.15B in 2025, and it burned cash on R&D and commercialization. Revenue is gro
The RTGel platform is patented and hard to copy—competitors like Johnson & Johnson and Pfizer have tried similar approaches but haven't matched the sustained-release profile. However, the moat is eroding: generic mitomycin is already used off-label, and new en
Key events, in time order
UroGen gains research license and exclusive options to up to three oncology products using IntraGel's biodegradable sustained-release gel platform, plus exclusive rights to acquire TumoCure worldwide, with up to $7M equity investment.
ZUSDURI revenue $50.4M, up 73% QoQ; total revenue up 199% YoY
Earnings date set, market awaits results
Institutional holding change, indicating capital movement
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
